Federal Circuit: Cancer Treatment Patent Not Properly Enabled Or Disclosed
WASHINGTON, D.C. — A biopharmaceutical company’s patent on a cancer therapy called antibody-drug conjugates (ADCs) is invalid for lack of written description and lack of enablement, a Federal Circuit U.S. Court...To view the full article, register now.
Already a subscriber? Click here to view full article